Lippincott Journals Subscribers, use your username or email along with your password to log in.
Registered users can save articles, searches, and manage email alerts.
All registration fields are required.
Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Friend's E-mail is Invalid
Your message has been successfully sent to your friend.
February 10th, 2014, Volume 36, Issue 3;
Valentin Goede, MD, elaborates on the clinical implications of the “paradigm-changing” CLL11 Phase III study that found improved responses for patients with chronic lymphocytic leukemia receiving obinutuzumab-chlorambucil compared with those receiving rituximab-chlorambucil.